CN104955471A - 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒 - Google Patents

使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒 Download PDF

Info

Publication number
CN104955471A
CN104955471A CN201380070468.1A CN201380070468A CN104955471A CN 104955471 A CN104955471 A CN 104955471A CN 201380070468 A CN201380070468 A CN 201380070468A CN 104955471 A CN104955471 A CN 104955471A
Authority
CN
China
Prior art keywords
substituted
deoxy
group
composition
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380070468.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·潘吉瓦尼
陈玮笙
H·莱弗勒
U·尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galecto Biotech AB
TUFTS MED, University of
Original Assignee
Galecto Biotech AB
TUFTS MED, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech AB, TUFTS MED, University of filed Critical Galecto Biotech AB
Publication of CN104955471A publication Critical patent/CN104955471A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380070468.1A 2012-11-15 2013-11-15 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒 Pending CN104955471A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726998P 2012-11-15 2012-11-15
US61/726,998 2012-11-15
PCT/US2013/070306 WO2014078655A1 (en) 2012-11-15 2013-11-15 Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor

Publications (1)

Publication Number Publication Date
CN104955471A true CN104955471A (zh) 2015-09-30

Family

ID=50731716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380070468.1A Pending CN104955471A (zh) 2012-11-15 2013-11-15 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒

Country Status (6)

Country Link
US (1) US20150320782A1 (de)
EP (1) EP2919802A4 (de)
JP (1) JP6366598B2 (de)
CN (1) CN104955471A (de)
CA (1) CA2926480A1 (de)
WO (1) WO2014078655A1 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108404118A (zh) * 2017-06-14 2018-08-17 张建宁 人源乳凝集素亚型蛋白的新用途
CN108602847A (zh) * 2015-12-18 2018-09-28 格莱克特生物技术公司 多晶型及方法
CN108602848A (zh) * 2015-11-09 2018-09-28 格莱克特生物技术公司 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN109563120A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN111032670A (zh) * 2017-05-12 2020-04-17 卡莱克汀科学有限责任公司 用于治疗系统性胰岛素抗性病症的化合物及其用途
CN112292386A (zh) * 2018-06-15 2021-01-29 百时美施贵宝公司 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN113980148A (zh) * 2021-11-10 2022-01-28 西北农林科技大学 一种中药蛴螬脂多糖及其制备方法和应用
CN117924453A (zh) * 2024-03-19 2024-04-26 广东现代汉方科技有限公司 一种甘露糖特异性凝集素重组植物蛋白的制备方法及应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200601A2 (en) 2014-06-25 2015-12-30 Tufts University Lymphangiogenesis inhibitors for cancer and for graft survival
JP6735680B2 (ja) * 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
CN106796243B (zh) * 2014-08-14 2018-10-12 国立大学法人广岛大学 判定早产和/或低体重儿生育的风险的方法和用于该方法的试剂盒
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
JP6707548B2 (ja) * 2015-01-16 2020-06-10 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
KR20260025887A (ko) 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
WO2017019770A1 (en) * 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
MX394409B (es) * 2016-03-04 2025-03-24 Galectin Sciences Llc Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
AU2017274195B2 (en) * 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US20200078335A1 (en) * 2017-05-01 2020-03-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis
EP3621973A4 (de) 2017-05-12 2021-10-27 Galectin Sciences, LLC Verbindungen zur vorbeugung und behandlung von erkrankungen und verwendung davon
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
KR102478553B1 (ko) * 2018-02-28 2022-12-16 한림제약(주) 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제
CA3122321A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
EP3886946A1 (de) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Vorrichtungen und verfahren zur präzisionsdosisverabreichung
JP7674276B2 (ja) * 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2021207312A1 (en) * 2020-04-07 2021-10-14 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating retinal nerve damage
US12312362B2 (en) 2020-10-06 2025-05-27 Idorsia Pharmaceuticals Ltd Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (de) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3-hemmende 2-hydroxycycloalkan-1-carbamoyl-derivate
CN116806219A (zh) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
RS67032B1 (sr) 2021-03-03 2025-08-29 Idorsia Pharmaceuticals Ltd Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CZ2023132A3 (cs) * 2023-04-04 2024-10-16 Ústav Chemických Procesů Av Čr, V. V. I. Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1636020A (zh) * 2001-11-21 2005-07-06 格里科基因系统公司 控制动物体内血管生成的方法
CN102066393A (zh) * 2008-05-16 2011-05-18 佛斯卡专利公司 半乳糖苷抑制剂的新颖的合成

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
EP2591786B1 (de) * 2003-10-16 2017-04-12 Cancure Limited Immunmodulierende Zusammensetzungen und ihre Verwendung
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401871D0 (sv) * 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US20110223177A1 (en) * 2008-09-09 2011-09-15 University Of East Anglia Treatment of fibrotic eye disorders
ES2652488T3 (es) * 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
US8557783B2 (en) * 2009-04-28 2013-10-15 Pharmaxis Pty Limited Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
US9243021B2 (en) * 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (de) * 2012-01-25 2013-07-31 Galecto Biotech AB Neuartige Galectin-Hemmer aus Galactosiden

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1636020A (zh) * 2001-11-21 2005-07-06 格里科基因系统公司 控制动物体内血管生成的方法
CN102066393A (zh) * 2008-05-16 2011-05-18 佛斯卡专利公司 半乳糖苷抑制剂的新颖的合成

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602848A (zh) * 2015-11-09 2018-09-28 格莱克特生物技术公司 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂
CN108602848B (zh) * 2015-11-09 2022-01-18 格莱克特生物技术公司 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂
CN108602847A (zh) * 2015-12-18 2018-09-28 格莱克特生物技术公司 多晶型及方法
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN109563120A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN109563120B (zh) * 2016-07-12 2022-12-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN111032670A (zh) * 2017-05-12 2020-04-17 卡莱克汀科学有限责任公司 用于治疗系统性胰岛素抗性病症的化合物及其用途
CN108404118A (zh) * 2017-06-14 2018-08-17 张建宁 人源乳凝集素亚型蛋白的新用途
CN112292386A (zh) * 2018-06-15 2021-01-29 百时美施贵宝公司 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN112292386B (zh) * 2018-06-15 2024-06-11 百时美施贵宝公司 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN113980148A (zh) * 2021-11-10 2022-01-28 西北农林科技大学 一种中药蛴螬脂多糖及其制备方法和应用
CN117924453A (zh) * 2024-03-19 2024-04-26 广东现代汉方科技有限公司 一种甘露糖特异性凝集素重组植物蛋白的制备方法及应用

Also Published As

Publication number Publication date
JP6366598B2 (ja) 2018-08-01
EP2919802A4 (de) 2016-09-14
WO2014078655A1 (en) 2014-05-22
CA2926480A1 (en) 2014-05-22
JP2016501849A (ja) 2016-01-21
EP2919802A1 (de) 2015-09-23
US20150320782A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
CN104955471A (zh) 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
JP2021104058A (ja) ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
Chen et al. Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3
RU2330861C2 (ru) Антитела к ростовому фактору соединительной ткани
EP3280728B1 (de) Alk7:actriib-heteromultimere und verwendungen davon
JP2020158546A (ja) 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
JP2022084709A (ja) 腎臓疾患を治療するための組成物および方法
JP6437462B2 (ja) 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
WO2018081074A1 (en) Neutralizing anti-tl1a monoclonal antibodies
JP2002543837A (ja) 組換えセトマンナン結合性レクチン
EA030332B1 (ru) Гликозилированные полипептиды сывороточного амилоида р, способы их получения, их применения и их фармацевтические препараты
PT1484338E (pt) Métodos e composições para inibição do crescimento de células neoplásicas.
US20160108114A1 (en) Compositions And Methods For Macular Degeneration
US20170095496A1 (en) Galactoside inhibitors for new uses
BRPI0710442A2 (pt) agentes de ligação de proteìna-4 secretada relacionada com frizzled(sfrp-4)
JP2001506847A (ja) 結合接着分子（ｊａｍ）、密着結合の膜貫通蛋白質
KR20000053277A (ko) 가용성 폴리펩티드
AU2001230594B2 (en) Novel scavenger receptors
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
WO2006129867A2 (en) ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN
JP2004215612A (ja) ガレクチン−８活性制御剤
US20170202915A1 (en) Lymphangiogenesis inhibitors for cancer and for graft survival
PT1121439E (pt) Método e composições para inibir o crescimento de células neoplásticas
EP4299588A2 (de) Behandlungsverfahren für augenerkrankungen
KR20120140097A (ko) 암 진단 및 치료용 조성물 및 방법

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150930